Acumen Pharmaceuticals, Inc.
ABOSNasdaq
$2.25
↑ +3.7%Jul 17 close · end-of-day
Price
1Y↑ +63.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$142.2M
Enterprise Value
$44.9M
P/E
—
P/S
—
P/B
1.6
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$113.3M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-129.5%
ROIC
—
Debt / Equity
0.4
Net Cash
$97.4M
Return 1Y
+52.0%
Company profile
Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage.
- CEO
- Daniel J. O'Connell
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- Virginia
- Website
- acumenpharm.com
Management & directors
- Meisner Derek MChief Legal Officer & Corp Sec
- Barton RussellChief Operating Officer
- Oconnell Daniel JosephChief Executive Officer
- Siemers EricChief Medical Officer
- Zuga MattCFO & Chief Business Officer
- Doherty James J.President and CDO
- Schacterle AmyChief Regulatory Officer
Roles derived from SEC Form 4 filings.
Earnings
ABOS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.33↓ -31.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$7.9M | -$19.6M | -$45.2M | -$61.1M | -$114.0M | -$123.8M |
| Net income | -$7.3M | -$100.6M | -$42.9M | -$52.4M | -$102.3M | -$121.3M |
| Diluted EPS | — | -$5.02 | -$1.06 | -$1.08 | -$1.71 | -$2.00 |
| Operating cash flow | -$7.5M | -$18.0M | -$35.2M | -$43.1M | -$86.2M | -$115.5M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$24.4M | -$32.3M | -$39.6M | -$30.4M | -$41.8M | -$26.5M | -$25.2M | -$21.1M |
| Net income | -$20.5M | -$29.8M | -$37.2M | -$28.8M | -$41.0M | -$26.5M | -$25.1M | -$20.7M |
| Diluted EPS | -$0.34 | -$0.50 | -$0.62 | -$0.48 | -$0.68 | -$0.44 | -$0.40 | -$0.33 |
| Operating cash flow | -$16.5M | -$24.6M | -$27.2M | -$34.1M | -$31.8M | -$30.5M | -$19.1M | -$24.1M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 20, 2026
Jul 15, 2026
- 5d agoAll You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to Buyfinance.yahoo.com
- 5d agoAre Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This Year?finance.yahoo.com
- 5d agoAcumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026finance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-17 | Porter Derrell | Sale | 13,040 | $2.33 | $30,318.00 | filing |
| 2026-06-17 | Porter Derrell | Option exercise | 13,040 | $1.07 | $13,952.80 | filing |
| 2026-06-16 | Porter Derrell | Sale | 12,800 | $2.33 | $29,772.80 | filing |
| 2026-06-15 | Porter Derrell | Sale | 6,460 | $2.35 | $15,148.70 | filing |
| 2026-06-15 | Porter Derrell | Option exercise | 6,460 | $1.07 | $6,912.20 | filing |
| 2026-06-09 | Fountain Nathan B | Sale | 6,400 | $2.23 | $14,272.64 | filing |
| 2026-06-03 | Ives Jeffrey L. | Award | 35,500 | $0.00 | $0.00 | filing |
| 2026-06-03 | Golumbeski George | Award | 35,500 | $0.00 | $0.00 | filing |
| 2026-06-03 | Stoppel Laura | Award | 35,500 | $0.00 | $0.00 | filing |
| 2026-06-03 | RA CAPITAL MANAGEMENT, LLC | Award | 35,500 | $0.00 | $0.00 | filing |
| 2026-06-03 | Fountain Nathan B | Award | 35,500 | $0.00 | $0.00 | filing |
| 2026-06-03 | Drapkin Kimberlee C | Award | 35,500 | $0.00 | $0.00 | filing |
| 2026-06-03 | Stalfort Sean | Award | 35,500 | $0.00 | $0.00 | filing |
| 2026-06-03 | Porter Derrell | Award | 35,500 | $0.00 | $0.00 | filing |
| 2026-03-16 | RA CAPITAL MANAGEMENT, LLC | Award | 6,060,606 | $3.30 | $20.0M | filing |
| 2026-03-06 | Meisner Derek M· Chief Legal Officer & Corp Sec | Sale | 2,090 | $3.26 | $6,813.40 | filing |
| 2026-03-06 | Meisner Derek M· Chief Legal Officer & Corp Sec | Option exercise | 2,090 | $1.85 | $3,866.50 | filing |
| 2026-02-27 | Meisner Derek M· Chief Legal Officer & Corp Sec | Sale | 9,406 | $3.01 | $28,311.12 | filing |
| 2026-02-27 | Meisner Derek M· Chief Legal Officer & Corp Sec | Option exercise | 9,406 | $1.85 | $17,401.10 | filing |
| 2026-01-28 | Meisner Derek M· Chief Legal Officer & Corp Sec | Sale | 2,671 | $3.00 | $8,017.27 | filing |
| 2026-01-28 | Meisner Derek M· Chief Legal Officer & Corp Sec | Option exercise | 2,671 | $1.85 | $4,941.35 | filing |
| 2026-01-26 | Meisner Derek M· Chief Legal Officer & Corp Sec | Sale | 15,085 | $3.00 | $45,262.54 | filing |
| 2026-01-26 | Meisner Derek M· Chief Legal Officer & Corp Sec | Option exercise | 15,085 | $1.85 | $27,907.25 | filing |
| 2026-01-23 | Meisner Derek M· Chief Legal Officer & Corp Sec | Sale | 5,633 | $1.90 | $10,717.91 | filing |
| 2026-01-22 | OConnell Daniel Joseph· Chief Executive Officer | Sale | 2,689 | $1.88 | $5,065.54 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.